Tobacco Treatment Comparison for Cancer Care
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 52 people enrolled
- Started
- 1 Mar 2024
- Ended
- 4 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transdermal Nicotine Patch
- Standard Telephone Counseling
- Varenicline
- Cancer-Targeted Telephone Counseling
- Mailed Information about Standard Care Resources
- Record updated
- 27 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Alive (per medical record)
- Diagnosed with cancer in the past 3 years
- Received care from a participating oncology clinic in the past year
- Has a current tobacco use status
- Does not have a preferred language other than English (missing language preference will be included)
- Valid address that is not a correctional facility or residential treatment/care facility
- No flag for patient cognitive impairment, activated health care power of attorney, or other health care agent (e.g., legally authorized representative) in the EHR; The following additional inclusion criteria must be met for inclusion in the CET
- Smoked combustible cigarettes in the past month
- Able to speak and understand English
- Willing to set a date to quit smoking in the next 60 days
- Willing to receive smoking treatment information
- Willing to complete study activities
Who cannot take part
- Currently receiving treatment for bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder
- No current suicidal ideation
- Suicide attempt in the past year
- Incarceration
- Unable to provide informed consent to treatment (i.e., cannot answer questions about study procedures or risks after hearing about the study)
Where in United States
- UW Carbone Cancer CenterMadison, United States
About the trial
What the trial wants to find out
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.
The 2 groups in the trial
- Low-Intensity Standard Smoking Cessation TreatmentExisting treatment, for comparison
2 weeks of nicotine patch therapy, 3 telephone counseling sessions, and information about quitline and National Cancer Institute text messaging support services (SmokefreeTXT)
Treatment: Transdermal Nicotine Patch, Standard Telephone Counseling, and Mailed Information about Standard Care Resources
- High-Intensity, Cancer-Targeted Smoking Cessation TreatmentTreatment being tested
12 weeks of varenicline therapy, 7 counseling sessions targeted to cancer patients, and information about quitline and SmokefreeTXT services
Treatment: Varenicline, Cancer-Targeted Telephone Counseling, and Mailed Information about Standard Care Resources
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparative Effectiveness Trial of Tobacco Cessation Treatments Among Cancer Patients Who Smoke
- Record updated
- 27 October 2025